3-4-CTMP

Under the Controlled Substances Act, 3,4-CTMP is federally covered by the controlled substance analogue provisions when it satisfies the definition in 21 U.S.C. § 802(32), falls outside the statutory exclusions, and is intended for human consumption under § 813. In those circumstances, it is treated as a Schedule I controlled substance for federal-law purposes, bringing possession under § 844 and manufacture, distribution, dispensing, and possession with intent to distribute under § 841. Sections 802(32) and 813 were added to the Act on 27 October 1986; 3,4-CTMP is not separately named in the DEA alphabetical controlled-substances list dated 27 August 2026.

3,4-CTMP is expressly listed as 3,4-dichloromethylphenidate in Schedule III, item 2(4), of the Controlled Drugs and Substances Act. The listing took effect on 5 May 2017. The Act prohibits possession, trafficking, possession for trafficking, import, export, possession for export, and production; possession, import, export, possession for export, and production may be authorized under the regulations.

3,4-CTMP is listed as item 106 in 《非药用类麻醉药品和精神药品目录》（2025年版） under the name 3,4-dichloromethylphenidate. The substance has been controlled since 1 October 2015, when the original scheduling measures and supplemental catalogue took effect. Production, trade, transport, use, storage, import, and export are prohibited; experimental research, scientific use, reference and comparison standards, and production intermediates are governed by the applicable provisions.

3,4-CTMP is covered by the generic structural definition for compounds derived from 2-phenethylamine in Anlage 1 Nr. 1 of the Neue-psychoaktive-Stoffe-Gesetz (NpSG), rather than by an exact-name listing. The NpSG took effect on 26 November 2016. Section 3(1) prohibits trade, placing on the market, manufacture, import, export, transit, acquisition, possession, and administration to another person. Under § 4(1), trade, placing on the market, administration to another person, and manufacture or import for the purpose of placing on the market are punishable by imprisonment for up to three years or a fine; simple acquisition and possession are not standalone criminal offenses under § 4. Recognized commercial, industrial, scientific, and official uses specified in § 3(2) are excepted, and qualifying medicinal products and narcotic drugs governed by the BtMG are excluded from the NpSG.

3,4-CTMP and its salts are listed as designated substances under Article 1, item 154 of 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令（平成十九年厚生労働省令第十四号）, which expressly names methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate. The designation took effect on 5 April 2014. Manufacture, import, sale, transfer, possession, purchase, acquisition, and use are prohibited when intended for, or undertaken for, purposes outside the medical and other uses permitted by ministerial ordinance.

3,4-CTMP, identified as metyl-2-(3,4-diklorofenyl)-2-(piperidin-2-yl)acetat, is expressly named as 3,4-diklorometyl-fenidat in Annex 1 to Förordning (1992:1554) om kontroll av narkotika and listed as 3,4-diklorometylfenidat in Förteckning I of Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. The Government added it to Annex 1 through SFS 2014:1480, while Läkemedelsverket added it to Förteckning I through LVFS 2014:11; both measures took effect on 16 January 2015. Förteckning I covers substances, plant materials, and fungi that normally have no medical use. Under Narkotikastrafflag (1968:64), unauthorized transfer, production for abuse, acquisition for transfer, procurement, processing, packaging, transport, storage, possession, use, sale, and offering for sale are prohibited. Separately authorized medical, scientific, especially important public-interest, and industrial channels remain available.

3,4-CTMP is expressly listed as 3,4-Dichlormethylphenidat in Annex 6, Verzeichnis e, of the Betäubungsmittelverzeichnisverordnung. Verzeichnis e substances are subject to the control measures applicable to Verzeichnis a narcotics and may be cultivated, manufactured, imported, exported, stored, used, or placed on the market only with authorization from the Federal Department of Home Affairs. Unauthorized conduct is punishable by up to three years' imprisonment or a monetary penalty.

3,4-Dichloromethylphenidate is expressly listed in the annex to Council of Ministers Decision No. 2016/9712, which subjects the listed substances to Law No. 2313 on the Control of Narcotic Drugs. Under Turkish Penal Code article 188, unauthorized manufacture, import, or export is punishable by twenty to thirty years' imprisonment and a judicial fine of 2,000 to 20,000 days; unauthorized sale, supply, transport, storage, purchase, acceptance, or possession is punishable by at least ten years' imprisonment and a judicial fine of 1,000 to 20,000 days. Article 191 prescribes two to five years' imprisonment for purchase, acceptance, or possession for personal use, or for use, and provides for deferred prosecution and supervised release in the circumstances stated there.

3,4-CTMP is expressly listed as 3,4-Dichloromethylphenidate (3,4-DCMP) in Schedule 2 Part II of the Misuse of Drugs Act 1971 and has been a Class B drug since 31 May 2017. Subject to regulations made under section 7, possession, production, and supply are unlawful.